CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 2, 2006, Pages 87-91

  Garcha, Robinder S ^a   Hughes, Alun D ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

ANP; BNP; Ca2+ activated potassium channels; CNP; Cyclic GMP; Natriuretic peptides; Neutral endopeptidase; Omapatrilat

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; ANGIOTENSIN I; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYCLIC GMP; GUANYLATE CYCLASE; IBERIOTOXIN; N(G) METHYLARGININE; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE SYNTHASE; OMAPATRILAT; POTASSIUM; VASOPEPTIDASE INHIBITOR;

ARTERY ENDOTHELIUM; ARTERY RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MYOGRAPHY; PROTEIN FUNCTION; VASODILATATION;

ARTERIES; CYCLIC GMP; HUMANS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; NATRIURETIC PEPTIDES; SUBCUTANEOUS TISSUE; VASODILATION;

EID: 33748649441     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.014     Document Type: Article

References (23)

1. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005;26(6):901-32.
2. Sagnella GA. Practical implications of current natriuretic peptide research. JRAAS 2000; 1(4):304-15.
3. Shen YT, Graham RM, Vatner SF. Effects of atrial natriuretic factor on blood flow distribution and vascular resistance in conscious dogs. Am J Physiol 1991;260(6 Pt 2):H1893-H1902.
4. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993;45(1):87-146.
5. Fink CA, Carlson JE, McTaggart PA et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1996;39(16):3158-68.
6. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial. Am J Hypertens 2004;17(2):103-11.
7. Hughes A, Thom S, Goldberg P, Martin G, Sever P. Direct effect of α-human atrial natriuretic peptide on human vasculature in vivo and in vitro. Clin Sci 1988;74:207-11.
8. van der ZK, Houben AJ, Kroon AA, De Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res 1999; 44(3):595-600.
9. Nakamura M, Arakawa N, Yoshida H, Makita S, Hiramori K. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 1994; 90(3):1210-14.
10. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
11. Prieto D, Benedito S, Nyborg NC. Heterogeneous involvement of endothelium in calcitonin gene-related peptide-induced relaxation in coronary arteries from rat. Br J Pharmacol 1991;103(3):1764-8.
12. Simonsen U, Wadsworth RM, Buus NH, Mulvany MJ. In vitro simultaneous measurements of relaxation and nitric oxide concentration in rat superior mesenteric artery. J Physiol (Lond) 1999;516(Pt 1):271-82.
13. Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 2000;129(1):184-92.
14. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-alquinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996;50(1):1-5.
15. Hughes AD, Nielsen H, Sever PS. The effect of atrial natriuretic peptide on human isolated resistance arteries. Br J Pharmacol 1989;97:1027-30.
16. Honing ML, Smits P, Morrison PJ, Burnett JC, Jr., Rabelink TJ. C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertens 2001;37(4):1179-83.
17. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003; 100(3):1426-31.
18. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertens 2000;35(6):1221-5.
19. d'Uscio LV, Quaschning T, Burnett JC, Jr., Luscher TF. Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition. Hypertens 2001;37(1):28-33.
20. Cargill RI, Barr CS, Coutie WJ, Struthers AD, Lipworth BJ. C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure. Thorax 1994;49(12):1247-9.
21. Hama N, Itoh H, Shirakami G, Suga S, Komatsu Y, Yoshimasa T, Tanaka I, Mori K, Nakao K. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem Biophys Res Commun 1994;198(3):1177-82.
22. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens 1993;7(3):245-50.
23. Cheung BM, Brown MJ. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension. J Hypertens 1994;12(4):449-54.